Ginkgo Bioworks Holdings annual ebitda
2019
2020
2021
2022
2023
2024
2025
Ginkgo Bioworks Holdings EBITDA Growth & History (DNA)
Ginkgo Bioworks Holdings's calculated EBITDA was −$256.3M for fiscal 2025.
View full Ginkgo Bioworks Holdings company overviewGinkgo Bioworks Holdings annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$256.3M | $240.4M | — |
| 2024 | 2024-12-31 | −$496.7M | $297.2M | — |
| 2023 | 2023-12-31 | −$793.9M | $1.37B | — |
| 2022 | 2022-12-31 | −$2.17B | −$367.0M | — |
| 2021 | 2021-12-31 | −$1.80B | −$1.68B | — |
| 2020 | 2020-12-31 | −$123.2M | −$62.3M | — |
| 2019 | 2019-12-31 | −$60.8M | — | — |
Ginkgo Bioworks Holdings quarterly ebitda
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$46.2M | −$3.3M | — |
| Q1 2026 | 2026-03-31 | −$58.6M | $7.6M | — |
| Q4 2025 | 2025-12-31 | −$72.5M | $15.5M | — |
| Q3 2025 | 2025-09-30 | −$74.8M | −$36.7M | — |
| Q2 2025 | 2025-06-30 | −$42.9M | $162.7M | — |
| Q1 2025 | 2025-03-31 | −$66.2M | $99.0M | — |
| Q4 2024 | 2024-12-31 | −$88.0M | $77.3M | — |
| Q3 2024 | 2024-09-30 | −$38.0M | $227.3M | — |
| Q2 2024 | 2024-06-30 | −$205.6M | −$39.1M | — |
| Q1 2024 | 2024-03-31 | −$165.1M | $31.7M | — |
| Q4 2023 | 2023-12-31 | −$165.3M | $49.9M | — |
| Q3 2023 | 2023-09-30 | −$265.3M | $380.7M | — |
| Q2 2023 | 2023-06-30 | −$166.5M | $472.3M | — |
| Q1 2023 | 2023-03-31 | −$196.8M | $469.6M | — |
| Q4 2022 | 2022-12-31 | −$215.2M | $1.46B | — |
| Q3 2022 | 2022-09-30 | −$646.0M | −$627.6M | — |
| Q2 2022 | 2022-06-30 | −$638.8M | −$586.0M | — |
| Q1 2022 | 2022-03-31 | −$666.4M | −$614.9M | — |
| Q4 2021 | 2021-12-31 | −$1.68B | — | — |
| Q3 2021 | 2021-09-30 | −$18.4M | — | — |
| Q2 2021 | 2021-06-30 | −$52.8M | — | — |
| Q1 2021 | 2021-03-31 | −$51.5M | — | — |
Ginkgo Bioworks Holdings ebitda trends
Over the last five fiscal years, Ginkgo Bioworks Holdings's ebitda decreased from −$123.2M to −$256.3M, a change of −$133.1M. The latest reported quarter, Q2 2026, shows −$46.2M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ginkgo Bioworks Holdings source filings ↗Community posts
Ginkgo links laboratory data services with Lilly’s TuneLab platform
Ginkgo ($DNA) Bioworks entered an agreement to provide experimental data-generation services to companies using Lilly’s ($LLY) TuneLab AI drug-discovery platform. Its Datapoints offering will supply small-molecule and antibody developabilit ...
Ginkgo joins a federally backed RNA-manufacturing project worth up to $17.5 million
Ginkgo Bioworks ($DNA) received a subcontract worth up to $17.5 million to participate in an ARPA-H program focused on RNA manufacturing. Waterfall Scientific is the prime contractor. The project, called ESCALATOR, is intended to combine co ...
